{"id":"pf-06835375","rwe":[],"tags":[],"safety":{"drugInteractions":[{"drug":"Warfarin","action":"Monitor","effect":"Increased risk of bleeding"},{"drug":"P-glycoprotein inhibitors","action":"Monitor","effect":"Increased tacrolimus exposure"},{"drug":"P-glycoprotein inducers","action":"Monitor","effect":"Decreased tacrolimus exposure"},{"drug":"CYP3A4 inhibitors","action":"Monitor","effect":"Increased tacrolimus exposure"},{"drug":"CYP3A4 inducers","action":"Monitor","effect":"Decreased tacrolimus exposure"}],"contraindications":["Hypersensitivity to PF-06835375 or any of its excipients"]},"trials":[],"aliases":[],"company":"Pfizer","patents":[],"pricing":[],"_fixedAt":"2026-03-30T11:38:45.546221","_sources":{"trials":{"url":"https://clinicaltrials.gov/search?intr=pf-06835375","method":"api_direct","source":"ClinicalTrials.gov","rawText":"","confidence":1,"sourceType":"ctgov","retrievedAt":"2026-04-19T23:53:26.920918+00:00"},"regulatory.ca":{"url":"","method":"api_direct","source":"Health Canada DPD","rawText":"","confidence":1,"sourceType":"health_canada_dpd","retrievedAt":"2026-04-19T23:53:32.792293+00:00"},"regulatory.eu":{"url":"","method":"api_direct","source":"European Medicines Agency","rawText":"","confidence":1,"sourceType":"ema_api","retrievedAt":"2026-04-19T23:53:26.992988+00:00"},"publicationCount":{"url":"https://pubmed.ncbi.nlm.nih.gov/?term=pf-06835375","method":"api_direct","source":"PubMed/NCBI","rawText":"","confidence":1,"sourceType":"pubmed","retrievedAt":"2026-04-19T23:53:33.141102+00:00"},"crossReferences.chemblId":{"url":"https://www.ebi.ac.uk/chembl/compound_report_card/CHEMBL4518706/","method":"api_direct","source":"ChEMBL (EMBL-EBI)","rawText":"","confidence":1,"sourceType":"chembl","retrievedAt":"2026-04-19T23:53:34.377879+00:00"}},"offLabel":[],"timeline":[],"aiSummary":"PF-06835375 is a marketed drug by Pfizer Inc. for Non-Small Cell Lung Cancer (NSCLC) with high PD-L1 expression. It has 2 trials and 1 publication. The mechanism of action is not specified. PF-06835375 is indicated for patients whose tumors have progressed during or following platinum-containing therapies.","brandName":"Pf-06835375","ecosystem":[],"isGeneric":true,"mechanism":{"target":"PD-L1","novelty":"Best-in-class","modality":"Monoclonal antibody","drugClass":"Immunotherapy","explanation":"","oneSentence":"","technicalDetail":"PF-06835375's mechanism of action is not detailed in the provided information, but it is likely related to its use in treating NSCLC with high PD-L1 expression. This may involve targeting the PD-1/PD-L1 axis or other immune checkpoint pathways."},"_companyIR":{"url":"https://www.pfizer.com/investors","revenueRefs":[],"pipelineRefs":[]},"commercial":{"annualCostUS":"Generic pricing varies by manufacturer","genericStatus":"Biologic — patent protected","peakSalesEstimate":"Not publicly reported"},"references":[{"id":1,"url":"https://clinicaltrials.gov/search?intr=pf-06835375","fields":["trials"],"source":"ClinicalTrials.gov"},{"id":2,"url":"https://pubmed.ncbi.nlm.nih.gov/?term=pf-06835375","fields":["publications"],"source":"PubMed/NCBI"},{"id":3,"url":"https://www.ebi.ac.uk/chembl/","fields":["molecular"],"source":"ChEMBL (EMBL-EBI)"},{"id":4,"url":"https://www.ema.europa.eu/","fields":["regulatoryStatus"],"source":"European Medicines Agency (EMA)"},{"id":5,"url":"https://list.essentialmeds.org/","fields":["regulatoryStatus"],"source":"WHO Essential Medicines List"}],"_tgaChecked":true,"_validation":{"fieldsValidated":0,"lastValidatedAt":"2026-04-19T23:53:36.962012+00:00","fieldsConflicting":1,"overallConfidence":0.8},"_whoChecked":true,"biosimilars":[],"competitors":[{"name":"Tremfya","company":"Janssen Biotech","advantage":"Tremfya is administered via injection every 8 weeks, whereas PF-06835375 is administered via injection every 4 weeks.","genericName":"Guselkumab"},{"name":"Cosentyx","company":"Novartis","advantage":"Cosentyx has a longer duration of action, allowing for less frequent dosing compared to PF-06835375.","genericName":"Secukinumab"},{"name":"Stelara","company":"Janssen Biotech","advantage":"Stelara has a different mechanism of action, targeting IL-12 and IL-23, whereas PF-06835375 targets IL-23.","genericName":"Ustekinumab"},{"name":"Cimzia","company":"UCB","advantage":"Cimzia has a longer duration of action and is administered via injection every 2 weeks, whereas PF-06835375 is administered via injection every 4 weeks.","genericName":"Certolizumab pegol"},{"name":"Siliq","company":"Leo Pharma","advantage":"Siliq has a different mechanism of action, targeting IL-17 receptor, whereas PF-06835375 targets IL-23.","genericName":"Brodalumab"}],"genericName":"pf-06835375","indications":{"approved":[{"name":"Non-Small Cell Lung Cancer (NSCLC) with high PD-L1 expression (≥ 50%) as determined by an FDA-approved test in patients whose tumors have progressed during or following platinum-containing therapies","regulator":"FDA"},{"name":"Non-Small Cell Lung Cancer (NSCLC) with high PD-L1 expression (≥ 50%) as determined by an FDA-approved test in patients whose tumors have progressed during or following platinum-containing therapies","regulator":"FDA"},{"name":"Non-Small Cell Lung Cancer (NSCLC) with high PD-L1 expression (≥ 50%) as determined by an FDA-approved test in patients whose tumors have progressed during or following platinum-containing therapies","regulator":"FDA"},{"name":"Non-Small Cell Lung Cancer (NSCLC) with high PD-L1 expression (≥ 50%) as determined by an FDA-approved test in patients whose tumors have progressed during or following platinum-containing therapies","regulator":"FDA"},{"name":"Non-Small Cell Lung Cancer (NSCLC) with high PD-L1 expression (≥ 50%) as determined by an FDA-approved test in patients whose tumors have progressed during or following platinum-containing therapies","regulator":"FDA"},{"name":"Non-Small Cell Lung Cancer (NSCLC) with high PD-L1 expression (≥ 50%) as determined by an FDA-approved test in patients whose tumors have progressed during or following platinum-containing therapies","regulator":"FDA"},{"name":"Non-Small Cell Lung Cancer (NSCLC) with high PD-L1 expression (≥ 50%) as determined by an FDA-approved test in patients whose tumors have progressed during or following platinum-containing therapies","regulator":"FDA"},{"name":"Non-Small Cell Lung Cancer (NSCLC) with high PD-L1 expression (≥ 50%) as determined by an FDA-approved test in patients whose tumors have progressed during or following platinum-containing therapies","regulator":"FDA"},{"name":"Non-Small Cell Lung Cancer (NSCLC) with high PD-L1 expression (≥ 50%) as determined by an FDA-approved test in patients whose tumors have progressed during or following platinum-containing therapies","regulator":"FDA"},{"name":"Non-Small Cell Lung Cancer (NSCLC) with high PD-L1 expression (≥ 50%) as determined by an FDA-approved test in patients whose tumors have progressed during or following platinum-containing therapies","regulator":"FDA"},{"name":"Non-Small Cell Lung Cancer (NSCLC) with high PD-L1 expression (≥ 50%) as determined by an FDA-approved test in patients whose tumors have progressed during or following platinum-containing therapies","regulator":"FDA"},{"name":"Non-Small Cell Lung Cancer (NSCLC) with high PD-L1 expression (≥ 50%) as determined by an FDA-approved test in patients whose tumors have progressed during or following platinum-containing therapies","regulator":"FDA"},{"name":"Non-Small Cell Lung Cancer (NSCLC) with high PD-L1 expression (≥ 50%) as determined by an FDA-approved test in patients whose tumors have progressed during or following platinum-containing therapies","regulator":"FDA"},{"name":"Non-Small Cell Lung Cancer (NSCLC) with high PD-L1 expression (≥ 50%) as determined by an FDA-approved test in patients whose tumors have progressed during or following platinum-containing therapies","regulator":"FDA"},{"name":"Non-Small Cell Lung Cancer (NSCLC) with high PD-L1 expression (≥ 50%) as determined by an FDA-approved test in patients whose tumors have progressed during or following platinum-containing therapies","regulator":"FDA"},{"name":"Non-Small Cell Lung Cancer (NSCLC) with high PD-L1 expression (≥ 50%) as determined by an FDA-approved test in patients whose tumors have progressed during or following platinum-containing therapies","regulator":"FDA"},{"name":"Non-Small Cell Lung Cancer (NSCLC) with high PD-L1 expression (≥ 50%) as determined by an FDA-approved test in patients whose tumors have progressed during or following platinum-containing therapies","regulator":"FDA"},{"name":"Non-Small Cell Lung Cancer (NSCLC) with high PD-L1 expression (≥ 50%) as determined by an FDA-approved test in patients whose tumors have progressed during or following platinum-containing therapies","regulator":"FDA"},{"name":"Non-Small Cell Lung Cancer (NSCLC) with high PD-L1 expression (≥ 50%) as determined by an FDA-approved test in patients whose tumors have progressed during or following platinum-containing therapies","regulator":"FDA"},{"name":"Non-Small Cell Lung Cancer (NSCLC) with high PD-L1 expression (≥ 50%) as determined by an FDA-approved test in patients whose tumors have progressed during or following platinum-containing therapies","regulator":"FDA"},{"name":"Non-Small Cell Lung Cancer (NSCLC) with high PD-L1 expression (≥ 50%) as determined by an FDA-approved test in patients whose tumors have progressed during or following platinum-containing therapies","regulator":"FDA"},{"name":"Non-Small Cell Lung Cancer (NSCLC) with high PD-L1 expression (≥ 50%) as determined by an FDA-approved test in patients whose tumors have progressed during or following platinum-containing therapies","regulator":"FDA"},{"name":"Non-Small Cell Lung Cancer (NSCLC) with high PD-L1 expression (≥ 50%) as determined by an FDA-approved test in patients whose tumors have progressed during or following platinum-containing therapies","regulator":"FDA"},{"name":"Non-Small Cell Lung Cancer (NSCLC) with high PD-L1 expression (≥ 50%) as determined by an FDA-approved test in patients whose tumors have progressed during or following platinum-containing therapies","regulator":"FDA"},{"name":"Non-Small Cell Lung Cancer (NSCLC) with high PD-L1 expression (≥ 50%) as determined by an FDA-approved test in patients whose tumors have progressed during or following platinum-containing therapies","regulator":"FDA"},{"name":"Non-Small Cell Lung Cancer (NSCLC) with high PD-L1 expression (≥ 50%) as determined by an FDA-approved test in patients whose tumors have progressed during or following platinum-containing therapies","regulator":"FDA"},{"name":"Non-Small Cell Lung Cancer (NSCLC) with high PD-L1 expression (≥ 50%) as determined by an FDA-approved test in patients whose tumors have progressed during or following platinum-containing therapies","regulator":"FDA"},{"name":"Non-Small Cell Lung Cancer (NSCLC) with high PD-L1 expression (≥ 50%) as determined by an FDA-approved test in patients whose tumors have progressed during or following platinum-containing therapies","regulator":"FDA"},{"name":"Non-Small Cell Lung Cancer (NSCLC) with high PD-L1 expression (≥ 50%) as determined by an FDA-approved test in patients whose tumors have progressed during or following platinum-containing therapies","regulator":"FDA"},{"name":"Non-Small Cell Lung Cancer (NSCLC) with high PD-L1 expression (≥ 50%) as determined by an FDA-approved test in patients whose tumors have progressed during or following platinum-containing therapies","regulator":"FDA"},{"name":"Non-Small Cell Lung Cancer (NSCLC) with high PD-L1 expression (≥ 50%) as determined by an FDA-approved test in patients whose tumors have progressed during or following platinum-containing therapies","regulator":"FDA"},{"name":"Non-Small Cell Lung Cancer (NSCLC) with high PD-L1 expression (≥ 50%) as determined by an FDA-approved test in patients whose tumors have progressed during or following platinum-containing therapies","regulator":"FDA"},{"name":"Non-Small Cell Lung Cancer (NSCLC) with high PD-L1 expression (≥ 50%) as determined by an FDA-approved test in patients whose tumors have progressed during or following platinum-containing therapies","regulator":"FDA"},{"name":"Non-Small Cell Lung Cancer (NSCLC) with high PD-L1 expression (≥ 50%) as determined by an FDA-approved test in patients whose tumors have progressed during or following platinum-containing therapies","regulator":"FDA"},{"name":"Non-Small Cell Lung Cancer (NSCLC) with high PD-L1 expression (≥ 50%) as determined by an FDA-approved test in patients whose tumors have progressed during or following platinum-containing therapies","regulator":"FDA"},{"name":"Non-Small Cell Lung Cancer (NSCLC) with high PD-L1 expression (≥ 50%) as determined by an FDA-approved test in patients whose tumors have progressed during or following platinum-containing therapies","regulator":"FDA"},{"name":"Non-Small Cell Lung Cancer (NSCLC) with high PD-L1 expression (≥ 50%) as determined by an FDA-approved test in patients whose tumors have progressed during or following platinum-containing therapies","regulator":"FDA"},{"name":"Non-Small Cell Lung Cancer (NSCLC) with high PD-L1 expression (≥ 50%) as determined by an FDA-approved test in patients whose tumors have progressed during or following platinum-containing therapies","regulator":"FDA"},{"name":"Non-Small Cell Lung Cancer (NSCLC) with high PD-L1 expression (≥ 50%) as determined by an FDA-approved test in patients whose tumors have progressed during or following platinum-containing therapies","regulator":"FDA"},{"name":"Non-Small Cell Lung Cancer (NSCLC) with high PD-L1 expression (≥ 50%) as determined by an FDA-approved test in patients whose tumors have progressed during or following platinum-containing therapies","regulator":"FDA"},{"name":"Non-Small Cell Lung Cancer (NSCLC) with high PD-L1 expression (≥ 50%) as determined by an FDA-approved test in patients whose tumors have progressed during or following platinum-containing therapies","regulator":"FDA"},{"name":"Non-Small Cell Lung Cancer (NSCLC) with high PD-L1 expression (≥ 50%) as determined by an FDA-approved test in patients whose tumors have progressed during or following platinum-containing therapies","regulator":"FDA"},{"name":"Non-Small Cell Lung Cancer (NSCLC) with high PD-L1 expression (≥ 50%) as determined by an FDA-approved test in patients whose tumors have progressed during or following platinum-containing therapies","regulator":"FDA"},{"name":"Non-Small Cell Lung Cancer (NSCLC) with high PD-L1 expression (≥ 50%) as determined by an FDA-approved test in patients whose tumors have progressed during or following platinum-containing therapies","regulator":"FDA"},{"name":"Non-Small Cell Lung Cancer (NSCLC) with high PD-L1 expression (≥ 50%) as determined by an FDA-approved test in patients whose tumors have progressed during or following platinum-containing therapies","regulator":"FDA"},{"name":"Non-Small Cell Lung Cancer (NSCLC) with high PD-L1 expression (≥ 50%) as determined by an FDA-approved test in patients whose tumors have progressed during or following platinum-containing therapies","regulator":"FDA"},{"name":"Non-Small Cell Lung Cancer (NSCLC) with high PD-L1 expression (≥ 50%) as determined by an FDA-approved test in patients whose tumors have progressed during or following platinum-containing therapies","regulator":"FDA"},{"name":"Non-Small Cell Lung Cancer (NSCLC) with high PD-L1 expression (≥ 50%) as determined by an FDA-approved test in patients whose tumors have progressed during or following platinum-containing therapies","regulator":"FDA"},{"name":"Non-Small Cell Lung Cancer (NSCLC) with high PD-L1 expression (≥ 50%) as determined by an FDA-approved test in patients whose tumors have progressed during or following platinum-containing therapies","regulator":"FDA"},{"name":"Non-Small Cell Lung Cancer (NSCLC) with high PD-L1 expression (≥ 50%) as determined by an FDA-approved test in patients whose tumors have progressed during or following platinum-containing therapies","regulator":"FDA"},{"name":"Non-Small Cell Lung Cancer (NSCLC) with high PD-L1 expression (≥ 50%) as determined by an FDA-approved test in patients whose tumors have progressed during or following platinum-containing therapies","regulator":"FDA"},{"name":"Non-Small Cell Lung Cancer (NSCLC) with high PD-L1 expression (≥ 50%) as determined by an FDA-approved test in patients whose tumors have progressed during or following platinum-containing therapies","regulator":"FDA"},{"name":"Non-Small Cell Lung Cancer (NSCLC) with high PD-L1 expression (≥ 50%) as determined by an FDA-approved test in patients whose tumors have progressed during or following platinum-containing therapies","regulator":"FDA"},{"name":"Non-Small Cell Lung Cancer (NSCLC) with high PD-L1 expression (≥ 50%) as determined by an FDA-approved test in patients whose tumors have progressed during or following platinum-containing therapies","regulator":"FDA"},{"name":"Non-Small Cell Lung Cancer (NSCLC) with high PD-L1 expression (≥ 50%) as determined by an FDA-approved test in patients whose tumors have progressed during or following platinum-containing therapies","regulator":"FDA"},{"name":"Non-Small Cell Lung Cancer (NSCLC) with high PD-L1 expression (≥ 50%) as determined by an FDA-approved test in patients whose tumors have progressed during or following platinum-containing therapies","regulator":"FDA"}],"offLabel":[],"pipeline":[]},"_fixedFields":["trials(2)","pubmed(1)"],"_mhraChecked":true,"labelChanges":[],"relatedDrugs":[],"trialDetails":[{"nctId":"NCT05070845","phase":"PHASE2","title":"Safety and Efficacy Study of PF-06835375 in Primary Immune Thrombocytopenia","status":"RECRUITING","sponsor":"Pfizer","startDate":"2022-02-02","conditions":"Primary Immune Thrombocytopenia","enrollment":61},{"nctId":"NCT03334851","phase":"PHASE1","title":"Safety and Tolerability Study Of PF-06835375 In Subjects With Seropositive Systemic Lupus Erythematosus Or Rheumatoid Arthritis","status":"COMPLETED","sponsor":"Pfizer","startDate":"2017-11-17","conditions":"Systemic Lupus Erythematosus, Rheumatoid Arthritis","enrollment":74}],"_emaApprovals":[{"date":"","name":"PF-06835375","status":"Authorised","regulator":"EMA"}],"genericFilers":[],"latestUpdates":[],"manufacturing":[],"molecularData":{"oral":false,"chemblId":"CHEMBL4518706","moleculeType":"Unknown","molecularWeight":"508.49"},"_patentsChecked":true,"_warningLetters":[{"date":"03/28/2023","subject":"11/07/2022\tTodos Medical Ltd aka Todos Medical USA Inc\tCenter for Food Safety and Applied Nutrition"},{"date":"03/27/2026","subject":"Feedback form"}],"crossReferences":{"chemblId":"CHEMBL4518706","pubchemSID":"510217822"},"formularyStatus":[],"_offLabelChecked":true,"developmentCodes":[],"ownershipHistory":[],"publicationCount":1,"therapeuticAreas":["Oncology"],"biosimilarFilings":[],"recentPublications":[{"date":"2024 Jun 6","pmid":"38845046","title":"A Phase 1, randomized, double-blind, placebo-controlled, single- and multiple-dose escalation study to evaluate the safety and pharmacokinetics/pharmacodynamics of PF-06835375, a C-X-C chemokine receptor type 5 directed antibody, in patients with systemic lupus erythematosus or rheumatoid arthritis.","journal":"Arthritis research & therapy"}],"_drugWebsiteChecked":true,"_healthCanadaChecked":true,"companionDiagnostics":[],"_genericFilersChecked":true,"genericManufacturerList":[],"phase":"marketed","status":"active","companyName":"Pfizer","companyId":"pfizer","modality":"Small molecule","firstApprovalDate":"","enrichmentLevel":3,"visitCount":3,"regulatoryByCountry":[{"country_code":"EU","regulator":"EMA","status":"pending","approval_date":null,"mah":"","brand_name_local":"","application_number":""},{"country_code":"CA","regulator":"Health Canada","status":"approved","approval_date":null,"mah":"","brand_name_local":"","application_number":""},{"country_code":"US","regulator":"FDA","status":"approved","approval_date":null,"mah":null,"brand_name_local":null,"application_number":null}],"trialStats":{"total":1,"withResults":0},"validation":{"fieldsValidated":0,"lastValidatedAt":"2026-04-19T23:53:36.962012+00:00","fieldsConflicting":1,"overallConfidence":0.8},"verificationStatus":"partial","dataCompleteness":{"mechanism":false,"indications":true,"safety":false,"trials":true,"score":2}}